SMS Lifesciences India Limited (SMSLIFE.NS)

INR 1357.1

(3.57%)

EBITDA Summary of SMS Lifesciences India Limited

SMS Lifesciences India Limited's latest annual EBITDA in 2023 was 349.41 Million INR , down -2.24% from previous year.
SMS Lifesciences India Limited's latest quarterly EBITDA in 2024 Q1 was 162.84 Million INR , up 18.68% from previous quarter.
SMS Lifesciences India Limited reported an annual EBITDA of 341.76 Million INR in 2022, down -10.75% from previous year.
SMS Lifesciences India Limited reported an annual EBITDA of 489.1 Million INR in 2021, up 12.93% from previous year.
SMS Lifesciences India Limited reported a quarterly EBITDA of 92.92 Million INR for 2023 Q3, up 13.32% from previous quarter.
SMS Lifesciences India Limited reported a quarterly EBITDA of 81.99 Million INR for 2023 Q2, up 160.76% from previous quarter.

Annual EBITDA Chart of SMS Lifesciences India Limited (2023 - 2015)

Historical Annual EBITDA of SMS Lifesciences India Limited (2023 - 2015)

Year	EBITDA	EBITDA Growth
2023	349.41 Million INR	-2.24%
2022	341.76 Million INR	-10.75%
2021	489.1 Million INR	12.93%
2020	319.58 Million INR	16.78%
2019	276.66 Million INR	-25.2%
2018	372.61 Million INR	137.03%
2017	162.69 Million INR	-47.02%
2016	301.71 Million INR	1555976.81%
2015	-18.5 Thousand INR	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	162.84 Million INR	18.68%
2023 Q3	92.92 Million INR	13.32%
2023 Q2	81.99 Million INR	160.76%
2023 Q1	31.44 Million INR	-33.68%
2023 Q4	113.59 Million INR	22.24%
2023 FY	- INR	-2.24%
2022 Q2	84.21 Million INR	-4.25%
2022 FY	- INR	-10.75%
2022 Q4	47.41 Million INR	-51.94%
2022 Q1	87.95 Million INR	2.16%
2022 Q3	98.66 Million INR	17.16%
2021 Q4	86.09 Million INR	1.35%
2021 Q3	84.94 Million INR	-17.36%
2021 Q1	82.74 Million INR	-11.32%
2021 FY	- INR	12.93%
2021 Q2	102.79 Million INR	24.22%
2020 Q1	66.98 Million INR	54.02%
2020 FY	- INR	16.78%
2020 Q4	93.3 Million INR	27.8%
2020 Q3	73.01 Million INR	-11.55%
2020 Q2	82.54 Million INR	23.24%
2019 Q2	92.46 Million INR	-6.86%
2019 FY	- INR	-25.2%
2019 Q4	43.48 Million INR	45.26%
2019 Q3	29.93 Million INR	-67.62%
2019 Q1	99.27 Million INR	6.41%
2018 Q3	115.54 Million INR	30.87%
2018 FY	- INR	137.03%
2018 Q4	93.29 Million INR	-19.26%
2018 Q1	69.31 Million INR	137.69%
2018 Q2	88.29 Million INR	27.38%
2017 FY	- INR	-47.02%
2017 Q4	29.16 Million INR	-47.56%
2017 Q1	43.57 Million INR	-36.0%
2017 Q2	34.2 Million INR	-21.5%
2017 Q3	55.6 Million INR	62.57%
2016 Q1	87.6 Million INR	0.0%
2016 Q2	56.21 Million INR	-35.84%
2016 FY	- INR	1555976.81%
2016 Q3	89.62 Million INR	59.45%
2016 Q4	68.08 Million INR	-24.04%
2015 FY	- INR	0.0%

Peer EBITDA Comparison of SMS Lifesciences India Limited

Name	EBITDA	EBITDA Difference
Biocon Limited	41.52 Billion INR	99.159%
Blue Jet Healthcare Limited	2.29 Billion INR	84.757%
Concord Biotech Limited	4.65 Billion INR	92.501%
Dishman Carbogen Amcis Limited	3.07 Billion INR	88.625%
Jubilant Ingrevia Limited	4.56 Billion INR	92.345%
Lyka Labs Limited	167.58 Million INR	-108.492%
Panacea Biotec Limited	-47.58 Million INR	834.363%
Piramal Pharma Limited	13.05 Billion INR	97.324%
Supriya Lifescience Limited	1.83 Billion INR	80.966%
Syngene International Limited	10.84 Billion INR	96.779%
TAKE Solutions Limited	-1.05 Billion INR	133.251%
Zota Health Care Limited	82.07 Million INR	-325.731%